A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AKCEA-ANGPTL3-LRX (ISIS 703802) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

Registry ID

ISIS 703802-CS3

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA ULC

Start date

2017-11-22

Completion date

2018-09-04

Last update

2017-08-21

Conditions

• FAMILIAL CHYLOMICRONEMIA SYNDROME

Related clinical trials

• AN OPEN-LABEL SAFETY STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) PREVIOUSLY TREATED WITH VOLANESORSEN (ISIS 304801)
• AN OPEN-LABEL EXTENSION STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

View on source registry